Puma Biotechnology (NASDAQ:PBYI) issued its quarterly earnings data on Monday. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.39, StockRatingsNetwork reports.
Puma Biotechnology (NASDAQ:PBYI) traded up 0.35% on Monday, hitting $243.33. The stock had a trading volume of 223,799 shares. Puma Biotechnology has a 52-week low of $33.70 and a 52-week high of $244.38. The stock has a 50-day moving average of $123.2 and a 200-day moving average of $101.3. The company’s market cap is $7.328 billion.
PBYI has been the subject of a number of recent research reports. Analysts at Citigroup Inc. raised their price target on shares of Puma Biotechnology from $99.00 to $292.00 in a research note on Wednesday, July 23rd. They now have a “buy” rating on the stock. On a related note, analysts at Leerink Swann raised their price target on shares of Puma Biotechnology from $144.00 to $300.00 in a research note on Wednesday, July 23rd. They now have an “outperform” rating on the stock.
Puma Biotechnology, Inc is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.